EMARKETER PRO+
New data sets, deeper insights, and flexible data visualizations.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More
Advertising & Sponsorship Opportunities
Boost your brand and generate demand with media programs.
Learn More

Events & Resources

Resources
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Cigna Group’s Express Scripts sues the Federal Trade Commission

The news: Cigna Group’s pharmacy benefit manager (PBM), Express Scripts, recently sued the Federal Trade Commission (FTC), demanding a retraction of an agency report that criticized pharma’s middlemen.

  • Express Scripts argues it’s been defamed by the report and is filing suit with the goal of having it removed from the FTC’s websites.

Zooming out: The report came on the heels of a two-year investigation by the FTC and alleges PBMs hold considerable sway over the drugs patients can access and the prices they pay for them.

  • For context, the three largest PBMs (OptumRx, Express Scripts, and CVS Caremark) processed nearly 80% of the approximately 6.6 billion prescriptions dispensed by US pharmacies in 2023.
  • Further, given vertical integrations with the US’ largest health insurers and retail and specialty pharmacies, PBMs also appear to be steering patients to affiliated pharmacies.
  • When the report was issued, the FTC disclosed its plans to sue the three largest PBMs over their business practices for negotiating drug prices.

PBMs won’t back down: In a House Committee on Oversight and Accountability hearing that took place after the report’s release, executives from the three largest PBMs argued that they pass through nearly all rebates to plan sponsors and provide cost savings to consumers.